StockData
Pelthos Therapeutics Inc. logo

Pelthos Therapeutics Inc. (PTHS) company profile

PTHSNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$6.84−0.31 (-4.34%)

Close on Nov 17, 2026Market cap $26.19MP/E –Yield –

About Pelthos Therapeutics

Biological Products, (No Diagnostic Substances), SIC 2836

Pelthos Therapeutics Inc. is a biopharmaceutical company that commercializes treatments for dermatological conditions and pain management. The company maintains a portfolio of three therapies approved by the FDA: ZELSUVMI, a topical gel for molluscum contagiosum; XEPI, an antimicrobial cream for impetigo; and XEGLYZE, a pediculicide for head lice. In addition, the firm develops clinical-stage, non-opioid pain candidates targeting sodium channels. Its customer base includes adult and pediatric patients with skin conditions, as well as prescribing healthcare professionals such as pediatricians and dermatologists. The company distributes its commercial therapies through retail chains, mail-order services, and digital pharmacies.

The company conducts its primary operations from a leased 19,265-square-foot facility in Durham, North Carolina, which houses administrative offices, research laboratories, warehouses, and manufacturing space for active pharmaceutical ingredients. Pelthos holds worldwide rights to its head lice therapy, global rights excluding Japan for its molluscum contagiosum treatment, and rights within the United States for its impetigo treatment.

Summary of the business section of Pelthos Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Pelthos Therapeutics Inc.
Founded
2021
Headquarters
Durham, NC
Address
4020 Stirrup Creek Drive, Suite 110 27703
Phone
(919) 908-2422
Employees
92, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Nevada
Fiscal year ends
December 31
Auditor
CBIZ CPAs P.C., Hartford, Connecticut

Stock & identifiers

Ticker
PTHS
Former tickers
CHRO until Jul 2, 2025
Exchange
NYSE
IPO date
Feb 20, 2024
Shares outstanding
4M, Aug 10, 2026
Public float
$6.70M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Stock splits
1-for-10 reverse, Jul 2, 2025
SEC CIK
1919246
CUSIP
171126204
ISIN
US1711262048
FIGI
BBG01C9YP5V5
Share class FIGI
BBG01C9YP6S7
EIN
86-3335449

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Scott M. PleshaCEO and President, Director83,678
Knuettel Francis IICFO, Treas & Secty40,841
John M. GayChief Financial Officer30,518
Sai RangaraoChief Commercial Officer30,518
Matthew PaulsDirector13,578
Ezra M. FriedbergDirector202,556
Peter GreenleafDirector23,087
Todd C. DavisDirector1,575,331
Richard MalamutDirector28,462
Richard B. BaxterDirector19,108
Andrew J. EinhornDirector12,000
Pharmaceuticals Inc LigandDirector1,500,000
Chia-Lin SimmonsDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsOtherTotalvs. prior year
Scott M. Plesha
Chief Executive Officer
$219.80K$240.90K$1.13M$2.56M$5.16K$4.15M–
Francis Knuettel II
Former Chief Financial Officer; Former Chief Executive Officer (2)
$410.00K$331.65K$451.87K$1.09M$2.55K$2.29M+90%
Sai Rangarao
Chief Commercial Officer
$200.73K$176.00K$411.99K$932.79K$1.89K$1.72M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Feb 20, 2024
Offer price
$6.00
Securities offered
1,100,000
Gross proceeds
$6.60M
Exchange
NYSE American
Lock-up ends (est.)
Aug 18, 2024

“The offering of the IPO Shares is being made on a firm commitment basis with the initial public offering price of $6.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, the Company had a total of 92 full-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
May 21, 2026Auditor changeChange in certifying accountant (8-K Item 4.01)
Sep 16, 2025Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 2, 2025Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 27, 2025Name changeName changed from Channel Therapeutics Corp to Pelthos Therapeutics Inc.
Apr 17, 2025Auditor changeChange in certifying accountant (8-K Item 4.01)
Nov 15, 2024Name changeName changed from Chromocell Therapeutics Corp to Channel Therapeutics Corp
Apr 1, 2024Late filingNotification of late filing
Feb 20, 2024IPOInitial public offering priced (424B4 prospectus)
Feb 15, 2024ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?